Revenue
2022
2023
2024
2025
Exozymes Inc. (EXOZ)
Price$5.76Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $70,069 | $0 |
| Research & development | $3.7M | $1.9M | $527,480 | $376,682 |
| Operating expenses | $9.7M | $5.9M | $1.9M | $1.3M |
| Operating income | −$9.7M | −$5.9M | −$1.8M | −$1.3M |
| Operating margin | — | — | −2,563.50% | — |
| EBITDA | −$9.4M | −$5.7M | −$1.6M | −$1.2M |
| EBITDA margin | — | — | −2,282.44% | — |
| Net income | −$9.2M | −$5.9M | −$2.0M | −$1.4M |
| Net profit margin | — | — | −2,909.12% | — |
| Basic EPSper basic share | -$1.09 | -$0.89 | -$0.33 | -$0.17 |
| Diluted EPSper diluted share | -$1.09 | -$0.89 | -$0.33 | -$0.17 |
Owners
Reported shareholders
≈42.36%of listed shares
MDB Capital Holdings, LLC3.93M shares · Nov 8, 2024
View holders
| Holder | % owned |
|---|---|
MDB Capital Holdings, LLC | ≈42.36%3.93M shares |
Korman Tyler Paz | ≈7.86%729.12K shares |
Opgenorth Paul Hideo | ≈6.95%645.15K shares |
Bowie James Ulrich | ≈6.23%577.91K shares |
Rayo Edgardo Javier | ≈0.84%77.91K shares |
Perriman Damien Alan | ≈0.68%62.76K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.59%54.99K shares |
Davidson Kahn Capital Management, LLC | 0.27%25K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.25%23.41K shares |
Heltzen Michael | ≈0.11%10.63K shares |
BlackRock, Inc. | 0.10%9.61K shares |
Nawaz Fouad | ≈0.10%9.49K shares |
VANGUARD FIDUCIARY TRUST CO | 0.10%9.43K shares |
MORGAN STANLEY | 0.01%1.25K shares |
Tower Research Capital LLC (TRC) | <0.01%349 shares |
UBS Group AG | <0.01%203 shares |
BARCLAYS PLC | <0.01%75 shares |
MARLETT CHRISTOPHER A | —— shares |
DIGIANDOMENICO ANTHONY | —— shares |
HAYAT MOHAMMAD | —— shares |
Percentages use 9.28M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 9, 2026Form 4 | Korman Tyler PazChief Scientific Officer | SellCOMMON STOCK | 750 | $10.53 | $7.9K | 729.1K |
| Apr 8, 2026Form 4 | Korman Tyler PazChief Scientific Officer | SellCOMMON STOCK | 750 | $10.04 | $7.5K | 729.9K |
| Jul 2, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 1.0K | $10.22 | $10.6K | 10.6K |
| Jan 17, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 1.8K | $10.78 | $19.0K | 3.9K |
| Jan 16, 2025Form 4 | Heltzen MichaelChief Executive Officer | BuyCommon Stock | 121 | $10.72 | $1.3K | 2.1K |
Community posts
eXoZymes selects Curia to scale up its NCT manufacturing process
eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and pro ...
